{"created":"2021-03-01T06:12:48.540116+00:00","id":8773,"links":{},"metadata":{"_buckets":{"deposit":"6fd2c3c3-8df8-471c-8944-17566b901695"},"_deposit":{"id":"8773","owners":[],"pid":{"revision_id":0,"type":"depid","value":"8773"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00008773","sets":["453:456","471:537:538:915"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Clinical Significance of Ribonucleotide Reductase M1 Expression in Patients with Intrahepatic Cholangiocartinoma : Association with Gemcitabine Resistance"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"28","bibliographicPageStart":"21","bibliographicVolumeNumber":"129","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【目的】Gemcitabine(以下GEM)の代謝経路において, リボヌクレオチド還元酵素の調節サブユニットであるRibonucleotide Reductase M1(以下RRM1)はGEMの作用機序に重要な働きを示すkey molecularとされている. 本研究の目的は, 肝内胆管癌におけるRRM1発現を免疫組織化学にて検討し, GEM基盤の術前化学療法の効果とRRM1発現との関連を明らかにすることにある. 【対象と方法】1992年1月から2012年12月までに当科で根治切除が施行された肝内胆管癌43例を対象とした. 術前に高度局所進展のため根治切除が困難・不能と診断された4例に対して, GEM基盤の術前化学療法(GEM単剤2例, GEM+TS-1併用2例)を施行した. 術前化学療法の治療効果はRECISTガイドラインに準じて判定した. RRM1発現は免疫組織化学により評価され, 陽性または陰性に分類した. 【結果】RRM1発現陽性は43例中27例(63%)であった. GEM基盤の術前化学療法が施行された4例全例で重篤な有害事象の発生なく, 化学療法前に立案していた術式の遂行が可能であった. 術前化学療法を施行した4例中3例はRRM1発現陽性であり, 腫瘍縮小率は11%, 14%, 25%であり, 治療効果は安定(SD)と判定された. 残り1例はRRM1発現陰性で, 腫瘍縮小率は68%であり, 部分奏功(PR)と判定された. 【結論】GEM基盤の術前化学療法の効果はRRM1発現と関連していることが示唆される. 高度局所進展を伴う肝内胆管癌に対するGEM基盤の術前化学療法は安全に施行でき, かつ立案術式を遂行可能であるため, 十分に認容されるものである.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"61130","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Katada, Tomohiro"}]},{"nameIdentifiers":[{"nameIdentifier":"61131","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Wakai, Toshifumi"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"堅田, 朋大"}],"nameIdentifiers":[{"nameIdentifier":"61128","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"若井, 俊文"}],"nameIdentifiers":[{"nameIdentifier":"61129","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"129(1)_21-28.pdf","filesize":[{"value":"3.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"129(1)_21-28.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/8773/files/129(1)_21-28.pdf"},"version_id":"454fdbea-b6d6-4d70-a070-644ffa3338d8"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"肝内胆管癌","subitem_subject_scheme":"Other"},{"subitem_subject":"Gemcitabine","subitem_subject_scheme":"Other"},{"subitem_subject":"RRM1","subitem_subject_scheme":"Other"},{"subitem_subject":"術前化学療法","subitem_subject_scheme":"Other"},{"subitem_subject":"外科切除","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"肝内胆管癌におけるRibonucleotide Reductase M1発現の臨床学的意義 : Gemcitabine治療抵抗性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"肝内胆管癌におけるRibonucleotide Reductase M1発現の臨床学的意義 : Gemcitabine治療抵抗性"},{"subitem_title":"肝内胆管癌におけるRibonucleotide Reductase M1発現の臨床学的意義 : Gemcitabine治療抵抗性","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","915"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-09-27"},"publish_date":"2016-09-27","publish_status":"0","recid":"8773","relation_version_is_last":true,"title":["肝内胆管癌におけるRibonucleotide Reductase M1発現の臨床学的意義 : Gemcitabine治療抵抗性"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:43:04.032283+00:00"}